Figure 1

Effects of minocycline on hBM-MSC stability. (A) hBM-MSC and astrocyte viabilities were analyzed with the MTT assay 24 hours after minocycline (0 to 10 μM) treatment. Minocycline did not affect hBM-MSC viability until 10 μM, whereas high concentrations (8 to 10 μM) decreased astrocyte viability. Points, mean; bars, SEM. (B) FACS analysis of the effect of minocycline on hBM-MSC phenotype. Wild-type (black lines) and minocycline-treated hBM-MSCs (red lines) were labeled with antibodies for MSC phenotypic surface markers. Minocycline did not change surface-marker expression; hBM-MSCs expressed CD90, CD44, and CD73 and lacked CD34, CD45, and HLA-DR. (C) The effect of minocycline on the differentiation potential of hBM-MSCs. Minocycline did not affect the differentiation capability of hBM-MSCs to adipogenic or osteogenic lineages, as stained by Oil Red O and Alizarin Red S, respectively. The results are representative of three independent experiments.